Nanopreparations to overcome multidrug resistance in cancer

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1748-1762

  Patel, Niravkumar R ^a   Pattni, Bhushan S ^a   Abouzeid, Abraham H ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Combination therapy; Multidrug resistance; Nanopreparations; Spheroid culture

Indexed keywords

CHEMOTHERAPEUTIC AGENTS; COMBINATION THERAPY; INTERSTITIAL FLUID PRESSURES; MULTIDRUG RESISTANCE; NANOPREPARATIONS; PHYSIOLOGICAL FACTORS; PHYSIOLOGICAL PROPERTIES; THERAPEUTIC MOLECULES;

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; MACHINERY; MOLECULES; NANOTECHNOLOGY; TUMORS;

PHYSIOLOGY;

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GOLD NANOPARTICLE; LIPOSOME; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; SMALL INTERFERING RNA; TARIQUIDAR; TOPOTECAN; UNINDEXED DRUG; VELIPARIB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL HYPOXIA; CELL PH; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; IC 50; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TISSUE PRESSURE; TUMOR SPHEROID; TUMOR VASCULARIZATION;

COMBINATION THERAPY; MULTIDRUG RESISTANCE; NANOPREPARATIONS; SPHEROID CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84888202520     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.08.004     Document Type: Review

References (240)

1. Hung L.W., et al. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 1998, 396(6712):703-707.
2. Yuan Y.R., et al. The crystal structure of the MJ0796 ATP-binding cassette. Implications for the structural consequences of ATP hydrolysis in the active site of an ABC transporter. J. Biol. Chem. 2001, 276(34):32313-32321.
3. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992, 8:67-113.
4. Schneider E., Hunke S. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol. Rev. 1998, 22(1):1-20.
5. Litman T., et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 2000, 113(Pt 11):2011-2021.
6. Volk E.L., et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 2002, 62(17):5035-5040.
7. Grant C.E., et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994, 54(2):357-361.
8. Allen J.D., et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000, 60(20):5761-5766.
9. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
10. Hardwick L.J., Velamakanni S., van Veen H.W. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br. J. Pharmacol. 2007, 151(2):163-174.
11. Robey R.W., et al. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007, 26(1):39-57.
12. Doyle L.A., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(26):15665-15670.
13. Nakagawa M., et al. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 1992, 52(22):6175-6181.
14. Horwitz S.B., et al. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr. 1993, 15:55-61.
15. Ford J.M., et al. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990, 50(6):1748-1756.
16. Abolhoda A., et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999, 5(11):3352-3356.
17. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26(4):239-257.
18. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
19. Indran I.R., et al. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 2011, 1807(6):735-745.
20. Reed J.C. Bcl-2 family proteins. Oncogene 1998, 17(25):3225-3236.
21. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15-16.
22. Moll U.M., et al. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 2005, 17(6):631-636.
23. Viktorsson K., Lewensohn R., Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv. Cancer Res. 2005, 94:143-196.
24. Mashima T., Tsuruo T. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updat. 2005, 8(6):339-343.
25. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65(20):3145-3167.
26. Ajabnoor G.M., Crook T., Coley H.M. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis. 2012, 3:e260.
27. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657.
28. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2(6):420-430.
29. Tschopp J., Martinon F., Hofmann K. Apoptosis: silencing the death receptors. Curr. Biol. 1999, 9(10):R381-R384.
30. Metzinger D.S., Taylor D.D., Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett. 2006, 236(2):302-308.
31. Schuyer M., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br. J. Cancer 2001, 85(9):1359-1367.
32. Sinicrope F.A., et al. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin. Cancer Res. 2008, 14(18):5810-5818.
33. Bradbury P.A., Middleton M.R. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004, 15(5):421-426.
34. Lage H., Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 1999, 125(3-4):156-165.
35. Li W., Melton D.W. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012, 31(19):2412-2422.
36. Youn C.K., et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 2004, 64(14):4849-4857.
37. Lord R.V., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8(7):2286-2291.
38. Cahill D.P., et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 2007, 13(7):2038-2045.
39. Britten R.A., Kuny S., Perdue S. Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. Br. J. Cancer 1999, 79(5-6):843-849.
40. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58(9):1808-1812.
41. Byun S.S., et al. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 2007, 69(1):34-37.
42. Caldas H., et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24(12):1994-2007.
43. Krieg A., et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br. J. Cancer 2002, 86(5):737-743.
44. Mahotka C., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int. J. Cancer 2002, 100(1):30-36.
45. Mahotka C., et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002, 9(12):1334-1342.
46. Mahotka C., et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999, 59(24):6097-6102.
47. Troeger A., et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007, 92(8):1043-1050.
48. Troger A., et al. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin. Padiatr. 2007, 219(3):127-133.
49. Wenzel M., et al. Novel survivin-related members of the inhibitor of apoptosis (IAP) family. Cell Death Differ. 2000, 7(7):682-683.
50. Mahon F.X., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68(23):9809-9816.
51. le Coutre P., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111(4):1834-1839.
52. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9(1):28-39.
53. Longo-Sorbello G.S., Bertino J.R. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 2001, 86(2):121-127.
54. Tannock I.F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001, 20(1-2):123-132.
55. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 2006, 4(2):61-70.
56. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58(7):1408-1416.
57. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441(7092):437-443.
58. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 1988, 48(10):2641-2658.
59. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007, 101(4):937-949.
60. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
61. Tredan O., et al. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99(19):1441-1454.
62. Gutmann R., et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 1992, 52(7):1993-1995.
63. Less J.R., et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 1992, 52(22):6371-6374.
64. Padera T.P., et al. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695.
65. Milosevic M., et al. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 2004, 14(3):249-258.
66. Hirst D.G., Denekamp J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 1979, 12(1):31-42.
67. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47(12):3039-3051.
68. Heldin C.H., et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4(10):806-813.
69. Curti B.D., et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993, 53(Suppl. 10):2204-2207.
70. Lee C.M., Tannock I.F. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br. J. Cancer 2006, 94(6):863-869.
71. Juweid M., et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992, 52(19):5144-5153.
72. Reilly R.M., et al. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 1995, 28(2):126-142.
73. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6(8):583-592.
74. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26(2):225-239.
75. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93(4):266-276.
76. Dewhirst M.W., et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer Suppl. 1996, 27:S247-S251.
77. Kallinowski F., et al. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int. J. Radiat. Oncol. Biol. Phys. 1990, 19(4):953-961.
78. Koch C.J. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol. 2002, 352:3-31.
79. Weber C.E., Kuo P.C. The tumor microenvironment. Surg. Oncol. 2012, 21(3):172-177.
80. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
81. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24(2):68-72.
82. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8(9):705-713.
83. Zhang X., Lin Y., Gillies R.J. Tumor pH and its measurement. J. Nucl. Med. 2010, 51(8):1167-1170.
84. Lee E.S., Gao Z., Bae Y.H. Recent progress in tumor pH targeting nanotechnology. J. Control. Release 2008, 132(3):164-170.
85. Brown J.M. Tumor hypoxia, drug resistance, and metastases. J. Natl. Cancer Inst. 1990, 82(5):338-339.
86. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4(6):437-447.
87. Shannon A.M., et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003, 29(4):297-307.
88. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11(6):393-410.
89. Ruan K., Song G., Ouyang G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009, 107(6):1053-1062.
90. Vaupel P., Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus. Clin. Biol. 2005, 12(1):5-10.
91. Brahimi-Horn M.C., Pouyssegur J. Oxygen, a source of life and stress. FEBS Lett. 2007, 581(19):3582-3591.
92. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3(10):721-732.
93. Shi Q., et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001, 20(28):3751-3756.
94. Shi Q., et al. Regulation of interleukin-8 expression by tumor-associated stress factors. J. Interferon Cytokine Res. 2001, 21(8):553-566.
95. Song X., et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother. Pharmacol. 2006, 58(6):776-784.
96. Jabr-Milane L.S., et al. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34(7):592-602.
97. Nooter K., et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1995, 1(11):1301-1310.
98. Fardel O., Lecureur V., Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27(8):1283-1291.
99. Yokoi K., Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res. 2004, 10(7):2299-2306.
100. Wykoff C.C., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60(24):7075-7083.
101. Koukourakis M.I., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res. 2001, 7(11):3399-3403.
102. Wojtkowiak J.W., et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharm. 2011, 8(6):2032-2038.
103. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resist. Updat. 2000, 3(1):39-47.
104. Gerweck L.E., Vijayappa S., Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 2006, 5(5):1275-1279.
105. Skarsgard L.D., et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer. Res. 1995, 15(1):219-223.
106. Vukovic V., Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75(8):1167-1172.
107. Williams A.C., Collard T.J., Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999, 18(21):3199-3204.
108. LeBoeuf R.A., et al. Intracellular acidification is associated with enhanced morphological transformation in Syrian hamster embryo cells. Cancer Res. 1992, 52(1):144-148.
109. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996, 56(24):5754-5757.
110. Bindra R.S., Glazer P.M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 2005, 569(1-2):75-85.
111. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1:119-150.
112. Li H., Fan X., Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 2007, 101(4):805-815.
113. Mbeunkui F., Johann D.J. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother. Pharmacol. 2009, 63(4):571-582.
114. Li L., Cole J., Margolin D.A. Cancer stem cell and stromal microenvironment. Ochsner J. 2013, 13(1):109-118.
115. Ponce de Leon V., Barrera-Rodriguez R. Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 2005, 5(1):20.
116. Desoize B., Gimonet D., Jardiller J.C. Cell culture as spheroids: an approach to multicellular resistance. Anticancer. Res. 1998, 18(6A):4147-4158.
117. Kerbel R.S., et al. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb. Symp. Quant. Biol. 1994, 59:661-672.
118. Broxterman H.J., Lankelma J., Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 2003, 6(3):111-127.
119. Shain K.H., Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001, 1(1):69-78.
120. Sethi T., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5(6):662-668.
121. Hodkinson P.S., Mackinnon A.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int. J. Radiat. Biol. 2007, 83(11-12):733-741.
122. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9(2):E128-E147.
123. Cuvier C., et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 1992, 44(3):509-517.
124. Colin de Verdiere A., et al. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 1994, 33(6):504-508.
125. Susa M., et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009, 9:399.
126. Wang F., et al. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5(5):3679-3692.
127. Patel N.R., et al. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416(1):296-299.
128. Song X.R., et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 2009, 37(3-4):300-305.
129. Patil Y., et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136(1):21-29.
130. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6(3):928-939.
131. Wong H.L., et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 2006, 116(3):275-284.
132. Dantzig A.H., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56(18):4171-4179.
133. Mistry P., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61(2):749-758.
134. Fracasso P.M., et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 2001, 19(12):2975-2982.
135. Lhomme C., et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 2008, 26(16):2674-2682.
136. Pusztai L., et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104(4):682-691.
137. Muller C., et al. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol. Pharmacol. 1995, 47(1):51-56.
138. Ross D.D., et al. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993, 82(4):1288-1299.
139. Lonn U., Lonn S., Stenkvist B. Reduced occurrence of mdr-1 amplification in stage-IV breast-cancer patients treated with tamoxifen compared with other endocrine treatments. Int. J. Cancer 1993, 53(4):574-578.
140. Bates S., et al. A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001, 92(6):1577-1590.
141. Rowinsky E.K., et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 1998, 16(9):2964-2976.
142. Takara K., Sakaeda T., Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 2006, 12(3):273-286.
143. Di Nicolantonio F., et al. Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs 2004, 15(9):861-869.
144. Globisch C., Pajeva I.K., Wiese M. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg. Med. Chem. 2006, 14(5):1588-1598.
145. Breedveld P., Beijnen J.H., Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 2006, 27(1):17-24.
146. Houghton P.J., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004, 64(7):2333-2337.
147. Wang J., et al. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials 2010, 31(15):4426-4433.
148. Li J.M., et al. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 2012, 33(9):2780-2790.
149. Zhao P., et al. Reversion of multidrug resistance in human glioma by RNA interference. Neurol. Res. 2008, 30(6):562-566.
150. Abbasi M., Lavasanifar A., Uludag H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med. Res. Rev. 2013, 33(1):33-53.
151. Navarro G., et al. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond.) 2012, 7(1):65-78.
152. Beh C.W., et al. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 2009, 10(1):41-48.
153. Chen A.M., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5(23):2673-2677.
154. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 2008, 3(6):761-776.
155. Cheng D., et al. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials 2012, 33(4):1170-1179.
156. van Vlerken L.E., et al. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007, 67(10):4843-4850.
157. Devalapally H., et al. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 2008, 14(10):3193-3203.
158. Devalapally H., et al. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer 2007, 121(8):1830-1838.
159. Deng W.G., et al. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 2007, 67(2):709-717.
160. Choi S.H., et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 2008, 68(3):545-554.
161. Prabha S., Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm. 2004, 1(3):211-219.
162. Xu L., et al. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 1999, 10(18):2941-2952.
163. Su X., et al. Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics. Mol. Pharm. 2013, 10(5):1901-1909.
164. Deng W.G., et al. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gene Ther. 2008, 15(1):29-39.
165. Safa A.R., Day T.W., Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 2008, 8(1):37-46.
166. Lee A.L., et al. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Mol. Biosyst. 2011, 7(5):1512-1522.
167. Bae S., et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012, 33(5):1536-1546.
168. Ueda K., et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006, 66(19):9682-9690.
169. Shuhendler A.J., et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2010, 119(2):255-269.
170. Shen J., et al. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012, 33(33):8613-8624.
171. Li S.D., Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann. N. Y. Acad. Sci. 2006, 1082:1-8.
172. Hu Q., et al. Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 2012, 33(27):6580-6591.
173. Jang Y.L., et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int. J. Pharm. 2012, 434(1-2):488-493.
174. Landen C.N., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65(15):6910-6918.
175. Guo D.D., et al. Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer. Biomaterials 2012, 33(7):2272-2281.
176. Gleixner K.V., et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 2010, 70(4):1513-1523.
177. Sun T.M., et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5(2):1483-1494.
178. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58(14):1532-1555.
179. Ambasta R.K., Sharma A., Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc. Cell 2011, 3:26.
180. Hurwitz H.I., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 2005, 23(15):3502-3508.
181. Filleur S., et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003, 63(14):3919-3922.
182. Mei J., et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp. Oncol. 2008, 30(1):29-34.
183. Kim S.H., et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 2006, 116(2):123-129.
184. Lee S.H., Kim S.H., Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 2007, 357(2):511-516.
185. Kim S.H., et al. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 2008, 129(2):107-116.
186. Murata N., et al. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 2008, 126(3):246-254.
187. Niola F., et al. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 2006, 5(2):174-179.
188. Tailor T.D., et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther. 2010, 9(6):1798-1808.
189. Chang D.K., et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 2009, 284(19):12905-12916.
190. Herringson T.P., Altin J.G. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int. J. Pharm. 2011, 411(1-2):206-214.
191. Nasongkla N., et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem. Int. Ed. Engl. 2004, 43(46):6323-6327.
192. Gomes-da-Silva L.C., et al. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int. J. Pharm. 2012, 434(1-2):9-19.
193. Abu Lila A.S., et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J. Control. Release 2009, 137(1):8-14.
194. Kunstfeld R., et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J. Invest. Dermatol. 2003, 120(3):476-482.
195. Schmitt-Sody M., et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 2003, 9(6):2335-2341.
196. Strieth S., et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer 2004, 110(1):117-124.
197. Strieth S., et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int. J. Cancer 2008, 122(2):452-460.
198. Sengupta S., et al. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol. Res. 2000, 42(5):459-464.
199. Lee C.M., et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002, 62(15):4282-4288.
200. Eichhorn M.E., et al. Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol. Ther. 2007, 6(6):920-929.
201. Wu J., et al. Vascular targeting of doxorubicin using cationic liposomes. Int. J. Pharm. 2007, 337(1-2):329-335.
202. Loi M., et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J. Control. Release 2010, 145(1):66-73.
203. Yan Z., et al. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics. Nanotechnology 2011, 22(41):415103.
204. Perche F., Torchilin V.P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 2013:705265.
205. Zhou J., et al. Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237(1):10-21.
206. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12(19-20):853-859.
207. Liu X.Q., et al. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol. Pharm. 2012, 9(10):2863-2874.
208. Wang X.L., et al. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol. Pharm. 2009, 6(3):738-746.
209. Bartholomeusz G., et al. In vivo therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1alpha) using single-walled carbon nanotubes noncovalently coated with siRNA. Nano Res. 2009, 2(4):279-291.
210. Reddy K.R., et al. Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. Prostate 2011, 71(16):1796-1809.
211. Lee K.A., Roth R.A., LaPres J.J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther. 2007, 113(2):229-246.
212. Majumder P.K., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10(6):594-601.
213. Rouf M.A., et al. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res. 2009, 19(4):322-331.
214. Iwase Y., Maitani Y. Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. Biol. Pharm. Bull. 2012, 35(6):975-979.
215. Shin H.C., et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 2009, 140(3):294-300.
216. Forrest M.L., et al. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J. Control. Release 2006, 116(2):139-149.
217. Milane L., Duan Z., Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 2011, 8(1):185-203.
218. Shapira A., et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14(3):150-163.
219. Wang J., et al. Antioxidative function and biodistribution of [GdC82(OH)22]n nanoparticles in tumor-bearing mice. Biochem. Pharmacol. 2006, 71(6):872-881.
220. Yin J.J., et al. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol. Pharmacol. 2008, 74(4):1132-1140.
221. Holden C.A., et al. Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery. Int. J. Nanomedicine 2010, 5:25-36.
222. Shen J., et al. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 2013, 34(5):1581-1590.
223. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162(1):45-55.
224. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol. (Camb.) 2013, 5(1):96-107.
225. Lee E.S., et al. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 2003, 90(3):363-374.
226. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103(2):405-418.
227. Sawant R.R., et al. Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials 2012, 33(15):3942-3951.
228. Shen M., et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J. Control. Release 2012, 161(3):884-892.
229. Poon Z., et al. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 2011, 5(6):4284-4292.
230. Mo R., et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv. Mater. 2012, 24(27):3659-3665.
231. Gu Y.J., et al. Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells. Int. J. Nanomedicine 2011, 6:2889-2898.
232. Kale A.A., Torchilin V.P. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug. Chem. 2007, 18(2):363-370.
233. Xu P., et al. Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 2006, 7(3):829-835.
234. Sawant R.M., et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 2006, 17(4):943-949.
235. Shen Y., et al. pH-responsive nanoparticles for cancer drug delivery. Methods Mol. Biol. 2008, 437:183-216.
236. Huang S., et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013, 7(3):2860-2871.
237. Huang S., et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 2013, 34(21):5294-5302.
238. Hirschhaeuser F., et al. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148(1):3-15.
239. Takagi A., et al. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer. Res. 2007, 27(1A):45-53.
240. Perche F., Patel N.R., Torchilin V.P. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J. Control. Release 2012, 164(1):95-102.